Envestnet Asset Management Inc. Purchases 4,343 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Envestnet Asset Management Inc. boosted its position in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 4.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,760 shares of the company’s stock after acquiring an additional 4,343 shares during the quarter. Envestnet Asset Management Inc. owned 0.23% of Omnicell worth $5,030,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in OMCL. MetLife Investment Management LLC grew its stake in shares of Omnicell by 55.4% during the first quarter. MetLife Investment Management LLC now owns 23,169 shares of the company’s stock worth $3,000,000 after buying an additional 8,257 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Omnicell by 6.4% during the first quarter. Rhumbline Advisers now owns 111,098 shares of the company’s stock worth $14,386,000 after buying an additional 6,657 shares during the last quarter. Great West Life Assurance Co. Can grew its stake in shares of Omnicell by 0.4% during the first quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock worth $5,036,000 after buying an additional 144 shares during the last quarter. Raymond James Trust N.A. grew its stake in shares of Omnicell by 10.9% during the first quarter. Raymond James Trust N.A. now owns 3,881 shares of the company’s stock worth $503,000 after buying an additional 382 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Omnicell by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock worth $109,901,000 after buying an additional 4,839 shares during the last quarter.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $70.95 on Friday. The firm’s 50-day moving average price is $59.07 and its 200-day moving average price is $55.67. Omnicell, Inc. has a 1-year low of $46.11 and a 1-year high of $125.17. The firm has a market capitalization of $3.20 billion, a P/E ratio of -177.38, a P/E/G ratio of 9.41 and a beta of 0.90. The company has a current ratio of 2.06, a quick ratio of 1.75 and a debt-to-equity ratio of 0.50.

Omnicell (NASDAQ:OMCL – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.20. Omnicell had a negative net margin of 1.39% and a positive return on equity of 5.38%. The firm had revenue of $297.67 million for the quarter, compared to analyst estimates of $286.32 million. Equities research analysts anticipate that Omnicell, Inc. will post 0.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on OMCL shares. Benchmark raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $68.00 target price on the stock in a research note on Monday, February 27th. Piper Sandler lifted their price target on shares of Omnicell from $55.00 to $66.00 and gave the stock an “overweight” rating in a report on Friday, January 27th. SVB Leerink reiterated a “market perform” rating on shares of Omnicell in a report on Friday, January 27th. KeyCorp lifted their price target on shares of Omnicell from $65.00 to $70.00 in a report on Wednesday, May 3rd. Finally, StockNews.com initiated coverage on shares of Omnicell in a report on Thursday, March 16th. They set a “hold” rating on the stock. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and an average target price of $72.22.

Insider Activity

In other news, Director Joanne B. Bauer sold 13,115 shares of the business’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $54.24, for a total transaction of $711,357.60. Following the completion of the sale, the director now directly owns 28,096 shares of the company’s stock, valued at $1,523,927.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 2.76% of the company’s stock.

Omnicell Profile

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.